SCHEMBL5545601

SCHEMBL5545601

Clc1cccc2c1[N]CCC2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 3/20 0.41
ADRA2A P08913 2/20 0.36
ADRA2B P18089 2/20 0.36
ADRA2C P18825 2/20 0.36
CYP1A2 P05177 2/20 0.36
CYP2A6 P11509 2/20 0.36
TSHR P16473 1/20 0.36
CYP2D6 P10635 1/20 0.35
ADRA1D P25100 1/20 0.35
ADRA1A P35348 1/20 0.35
ADRA1B P35368 1/20 0.35
PNMT P11086 1/20 0.35
NOS3 P29474 1/20 0.35
NPSR1 Q6W5P4 1/20 0.34
POLB P06746 1/20 0.33
HTR5A P47898 1/20 0.33
TAAR1 Q96RJ0 1/20 0.33
TAS1R3 Q7RTX0 1/20 0.32
TAS1R1 Q7RTX1 1/20 0.32
TAS1R2 Q8TE23 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1091403 0.76 ALOX12 (0.38) CYP1A2CYP2A6TSHRCYP2D6NOS3
SCHEMBL8860490 0.76 NOS3 (0.43) ACHETSHRNOS3NPSR1POLB
SCHEMBL5544284 0.76 NOS3 (0.39) TSHRNOS3BCL2L1BAD
SCHEMBL249643 0.76 BCL2L1 (0.48) CYP1A2TSHRPNMTNOS3BCL2L1
SCHEMBL5545432 0.76 TSHR (0.36) TSHRPNMTNOS3BCL2L1BAD
SCHEMBL5539619 0.76 NOS3 (0.37) ADRA2ATSHRNOS3HTR5ABCL2L1
Bromide SCHEMBL11832552 0.74 BCL2L1 (0.47) CYP1A2TSHRPNMTNOS3BCL2L1
SCHEMBL301029 0.72 NPC1 (0.41) HTR5A
SCHEMBL7019246 0.71 POLB (0.41) ACHECYP1A2CYP2A6TSHRCYP2D6
SCHEMBL1525254 0.71 ALDH1A1 (0.47) ACHETSHRPNMTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed
US-4971957-A ANTILIPEMIC AGENTS, ANTICHOLESTEROL AGENTS, BENZENECARBOXAMIDOPHOSPHONATES OR BENZENETHIOCARBOXAMIDOPHOSPHONATES OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 1990-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ACHE 4670/4885ADRA2A 746/4885ADRA2B 396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.